HCW Biologics is trading 5.41% lower at $1.88 after investors reacted to its September 24, 2026 announcement of a $1.5 million private placement. - The financing includes 903,614 pre-funded warrants and potential common warrants, creating dilution concerns. - Units were priced at $1.6599; common warrants would have a $1.66 exercise price, subject to stockholder approval. - The broader market is modestly higher, so the financing appears to be the primary catalyst rather than market-wide weakness.